|
Acalabrutinib recommended for orphan drug designation in Europe for three indications
|
26 February 2016 |
|
Brilique (ticagrelor) approved in EU for extended treatment of patients with history of heart attack
|
19 February 2016 |
|
AstraZeneca and Moderna Therapeutics announce new collaboration to co-develop and co-commercialise immuno-oncology mRNA therapeutics™
|
12 January 2016 |
|
AstraZeneca enhances long-term growth through oncology investment in Acerta Pharma
|
17 December 2015 |
|
AstraZeneca to strengthen therapy area franchise through acquisition of Takeda's respiratory business
|
16 December 2015 |
|
AstraZeneca to harness power of the Secretome and develop next-generation biologics in collaboration with new Wallenberg Centre for Protein Research
|
11 December 2015 |
|
AstraZeneca and Voluntis to test companion mobile app in ovarian cancer studies with the US National Cancer Institute
|
08 December 2015 |
|
AstraZeneca enters into agreement with Perrigo for rights to Entocort® in the US
|
23 November 2015 |
|
AstraZeneca strengthens cardiovascular and metabolic disease portfolio with acquisition of ZS Pharma
|
06 November 2015 |
|
AstraZeneca and Lilly expand immuno-oncology research collaboration with new combinations
|
22 October 2015 |